Introduction Ritonavir-boosted nirmatrelvir (N/r) is an antiviral which targets the main viral
protease, administered to prevent the progression of SARS-CoV-2 infection in patients at …

Background The coronavirus disease 2019 (COVID-19) pandemic has caused significant
morbidity and mortality in high-risk populations. Several therapeutics have been developed …

Background: According to the Evaluation of Protease Inhibition for COVID-19 in High-Risk
Patients (EPIC-HR) study, compared with a placebo, nirmatrelvir/ritonavir significantly …

Objective The efficacy of nirmatrelvir–ritonavir for hospitalized patients with COVID-19 has
not been fully established. Methods We conducted a retrospective analysis of hospitalized …

Nirmatrelvir‐ritonavir (NR) was approved to treat SARS‐CoV‐2 positive outpatients at high
risk of progression to severe disease, based on a randomized trial in unvaccinated patients …

ABSTRACT Background Ritonavir-boosted Nirmatrelvir (NMV-r), a protease inhibitor with in
vitro activity against SARS-CoV-2, has been shown to reduce risk of progression to severe …

Abstract Background The role of Nirmatrelvir plus ritonavir (NMV-r) in preventing post-acute
sequelae of SARS-CoV-2 infection (PASC) is unknown. The objective of this study is to …

Introduction: Vaccination against SARS-CoV-2 and the prevalence of Omicron variants have
reduced the risk of the severe clinical progress of COVID-19. However, the risk of …

Background Our objective was to evaluate the real world effectiveness of
nirmatrelvir/ritonavir to prevent severe COVID-19 while Omicron and its subvariants …

Background: Nirmatrelvir/Ritonavir is an orally administered anti-SARS-Cov-2 drug used in
mild-to-moderate COVID-19 patients. Our retrospective cohort study aims to evaluate the …